Cancer & SURVIVEiT News

SURVIVEiT Lung Cancer Experts The Top Lung Cancer Doctors

One-Of-A-Kind List of Lung Cancer Experts | The Top Lung Cancer Doctors

September 22, 2021

SURVIVEiT®’s interactive Cancer Navigation Tool was built by survivors and medical experts to help you practically and efficiently navigate cancer care. We took our collective experience and things we wish…

SURVIVEiT Guest Blog - Peggy Dennis - The Tools That Allow Me To Address My Cancer With Less Fear and More Hope

The Tools That Allow Me To Address My Cancer With Less Fear and More Hope

May 5, 2021

When asked how Step 1 (TESTiT) and STEP 2 (VERIFYiT) of our Cancer Navigation Tool played a major part in her journey, this is what Peggy has to say.  ——————————Guest…

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression

February 24, 2021

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression On February 22, 2021, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line…

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

June 16, 2020

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for…

A Cancer Patient’s Experience With Immunotherapy

June 10, 2020

After a cancer diagnosis, it’s important that you gather as much information as you can so you can truly advocate for yourself. This includes understanding your specific type of cancer…

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

June 2, 2020

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for…

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

June 2, 2020

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC On May 26, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb…

FDA approves brigatinib for ALK-positive metastatic NSCLC

June 2, 2020

FDA approves brigatinib for ALK-positive metastatic NSCLC On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive…

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

June 2, 2020

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line…